Screener
Ultragenyx Pharmaceutical RARE Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product sales | $112 | $81 | $201 | $172 |
| Royalty revenue | 102 | 86 | 149 | 134 |
| Total revenues | 214 | 167 | 350 | 306 |
| Operating expenses: | ||||
| Cost of sales | 34 | 23 | 64 | 52 |
| Research and development | 167 | 165 | 354 | 331 |
| Selling, general and administrative | 88 | 87 | 176 | 174 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's total revenue?
- Ultragenyx Pharmaceutical (RARE) reported total revenue of $214M in Q2 2026.
- How has Ultragenyx Pharmaceutical's total revenue changed year-over-year?
- Ultragenyx Pharmaceutical's total revenue increased by 28.1% year-over-year, from $167M to $214M.
- What is the long-term trend for Ultragenyx Pharmaceutical's total revenue?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's total revenue has grown at a 17.6% compound annual growth rate (CAGR), from $351.41M to $673.21M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Ultragenyx Pharmaceutical's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude